RIGL Latest Press Releases

-- May 12, 2026 --

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer PRNewswire 7:00 AM

-- May 5, 2026 --

Rigel Reports First Quarter 2026 Financial Results PRNewswire 4:01 PM

-- April 28, 2026 --

Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results PRNewswire 8:05 AM

-- April 7, 2026 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- March 31, 2026 --

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology PRNewswire 8:05 AM

-- March 3, 2026 --

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PRNewswire 4:01 PM

-- February 24, 2026 --

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update PRNewswire 8:05 AM

-- February 3, 2026 --

Rigel Appoints Michael P. Miller to the Board of Directors PRNewswire 8:05 AM

-- January 12, 2026 --

Rigel Provides Business Update and 2026 Outlook PRNewswire 8:05 AM

-- January 9, 2026 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- January 7, 2026 --

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 8:05 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software